Browsing Category

HD Clinical Trials

HD Clinical Trials, Hope

The Pharmaceutical Company, Genentech

Statement from Genentech.
“There’s an innate brilliance in each of us. It lives in the thousands of thoughts and feelings that move through our bodies each day. It comes to life in our expressions and movements. In how we connect with each other, and in the moments and memories we create together. 

Neurological conditions can dim this brilliance. They can create barriers that impede our ability to
communicate. To move. To remember. Over time, these diseases can rob us of our identities. 

Our hope is that through our work in neuroscience, combining new scientific understanding with clinical advancements, we can help preserve the unique qualities that make people who they are.” stories/preserving-what-makes-us-who-we-are

Author Therese Crutcher-Marin

Last December, Roche/Genentech announced the locations, including 20 sites in the U.S. and 6 in Canada, for their phase 3 study – called GENERATION HD1 – to test efficacy of the huntingtin-lowering therapy RG6042. To read full press release, visit  RG6042-GENERATION-HD1-Study-update-.pdf

We Can Never Lose HOPE……………..

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.

June 18, 2019 by
HD Clinical Trials

Enroll -HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort

Author Therese Crutcher-Marin

At this time, in the Huntington’s disease arena around the world, people are needed to participate in the exciting clinical trials being conducted.  Without people, very brave people, we cannot move forward in finding a cure for the cruelest disease on the planet; Huntington’s disease (HD).

Enroll-HD is a longitudinal, observational, multinational study that will integrate two existing Huntington’s Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.  To learn more about Enroll-HD, go to:  https://www.enroll-hd.org/

https://chdifoundation.org/huntingtons-disease-society-of-america-endorses-enroll-hd/

https://memory.ucsf.edu/enroll-hd

https://www.hda.org.uk/research/current-research-studies/enroll-hd

Enroll-HD is a “platform”

The idea is that this one study will make all other HD research easier, speeding up the process of developing new drugs and other treatments that really work. Rather than being restricted to a select group of researchers, it will be a resource for all HD science, making it faster and more efficient for other researchers to conduct their projects. This is why it’s called a platform, it supports other work.

To find clinic locations near you, go to:  https://www.enroll-hd.org/participate/clinic-locations/

As promised, HDBuzz’s Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD “observational study” here. https://en.hdbuzz.net/261

We Can Never Lose Hope…….

 

 

April 23, 2019 by